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Abstract
Gentamicin shows large variations in half-life and volume of distribution (Vd) within and
between individuals. Thus, monitoring and accurately predicting serum levels are required
to optimize effectiveness and minimize toxicity. Currently, two population pharmacokinetic
models are applied for predicting gentamicin doses in adults. For endocarditis patients the
optimal model is unknown. We aimed at: 1) creating an optimal model for endocarditis
patients; and 2) assessing whether the endocarditis and existing models can accurately pre-
dict serum levels. We performed a retrospective observational two-cohort study: one cohort
to parameterize the endocarditis model by iterative two-stage Bayesian analysis, and a sec-
ond cohort to validate and compare all three models. The Akaike Information Criterion and
the weighted sum of squares of the residuals divided by the degrees of freedom were used
to select the endocarditis model. Median Prediction Error (MDPE) and Median Absolute Pre-
diction Error (MDAPE) were used to test all models with the validation dataset. We built the
endocarditis model based on data from the modeling cohort (65 patients) with a fixed 0.277
L/h/70kg metabolic clearance, 0.698 (±0.358) renal clearance as fraction of creatinine clear-
ance, and Vd 0.312 (±0.076) L/kg corrected lean body mass. External validation with data
from 14 validation cohort patients showed a similar predictive power of the endocarditis
model (MDPE -1.77%, MDAPE 4.68%) as compared to the intensive-care (MDPE -1.33%,
MDAPE 4.37%) and standard (MDPE -0.90%, MDAPE 4.82%) models. All models accept-
ably predicted pharmacokinetic parameters for gentamicin in endocarditis patients. How-
ever, these patients appear to have an increased Vd, similar to intensive care patients. Vd
mainly determines the height of peak serum levels, which in turn correlate with bactericidal
activity. In order to maintain simplicity, we advise to use the existing intensive-care model in
clinical practice to avoid potential underdosing of gentamicin in endocarditis patients.
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Introduction
Infective endocarditis is an infection of the endothelial lining of the heart, most commonly
involving the valvular leaflets [1–5]. Infection can also involve intracardiac prosthetic material.
The most common causative pathogens are staphylococci (42.1%), streptococci (29.6%), and
enterococci (10.6%), but many microorganisms have been implicated in endocarditis [6–8].
Guidelines recommend the use of gentamicin combined with beta-lactams as antimicrobial
treatment, mainly for Gram-positive pathogens [9,10]. Beta-lactams are thought to increase
access of gentamicin to the bacterial cell membrane of Gram-positive micro-organisms, caus-
ing a synergistic effect [11].
Gentamicin, an aminoglycoside, is classified as bactericidal antimicrobial agent [6]. Its clin-
ical efficacy is predicted by the pharmacodynamic factor Cmax:MIC, which is the ratio of the
gentamicin peak level in serum (Cmax) and the minimum inhibitory concentration (MIC) of
the micro-organism [12]. For systemic infections, gentamicin needs to be administered intra-
venously, displaying a short half-life of 2–3 hours [11–13]. This hydrophilic molecule has a vol-
ume of distribution (Vd) similar to the extracellular fluid, and a clearance proportional to the
glomerular filtration rate (90% renal clearance) [12,14]. A small proportion of gentamicin is
cleared non-renally (CLm; 10%).
Gentamicin peak and trough levels in endocarditis are aimed at 9–12 mg/l and<0.5–1 mg/l
[15,16]. Therefore, body weight-based dosing is started with 3 mg/kg once daily [17,18]. Peak
levels determine effectiveness of gentamicin treatment [19], with optimum bactericidal activity
and prevention of resistance achieved with Cmax:MIC10 [13]. Trough levels determine both
ototoxicity (hearing loss, tinnitus) and nephrotoxicity (usually reversible), with decreasing
renal clearance causing drug accumulation [12,19]. Toxicity also depends on patient character-
istics (age, hydration status, blood pressure) and simultaneous medication with similar toxic
potential [11,12,20], and toxicity earlier in the course of treatment is observed with higher
peak levels (opposing previous reports [11,13]). Peak levels indeed correlate indirectly with
nephrotoxicity, via the area under the serum concentration-time curve (AUC) [21,22].
A starting dose of 3 mg/kg gentamicin causes individual peak levels to vary, caused by large
intra and inter individual variability of pharmacokinetic parameters (e.g. Vd). Therefore, ther-
apeutic drug monitoring (TDM) is advised for optimal dosing, applying serum gentamicin lev-
els as well as pharmacokinetic (PK) and pharmacodynamic principles [12,19]. Guiding dose
and dosing interval maximizes efficacy and minimizes toxicity. TDM has been shown to
decrease hospital stay, and the incidence of nephrotoxicity, mortality, costs [19]. Effects of
TDM on ototoxicity are less clear [12].
To support TDM, population pharmacokinetic (PPK) models for gentamicin have been
created using Bayesian statistics. These PPK models were created for different populations in
order to enable appropriate advise on the dose of gentamicin to start with [23]. Thereafter,
Bayesian feedback algorithms, using the model and associated errors, enable advise on dosage
adjustments based on few measured serum levels [12,14]. As a number of factors influence the
predicting ability of PPK models, standardizing protocols and region-specific use are recom-
mended [19,23]. Importantly, patients admitted on the intensive care unit (ICU) are shown to
have higher Vd (more extravasation of drugs), as compared with patients admitted to a stan-
dard ward. Therefore, two PPK models for dosing of gentamicin in adult patients are used in
the Netherlands [24]: one with a high Vd (0.336 L/kg; ICU model) and the other with a lower
Vd (0.273 L/kg; standard model), respectively.
Although the standard and ICU PPK models for gentamicin perform well [24], they have
never been validated in endocarditis patients. Current dosing according to the standard model
often results in insufficient peak levels and need for dose adjustment. Additionally, a higher
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Vd than standard was previously reported in a historical cohort of adult patients with endocar-
ditis [23]. We concluded that endocarditis might be a specific clinical entity for which develop-
ment of a separate PPK model is warranted. Therefore, the aims of this study were: 1) to create
a new PPK model for gentamicin treatment in endocarditis patients (further referred to as “the
endocarditis model”); and 2) to assess whether the endocarditis model, and the models cur-
rently used in clinical practice, can accurately predict serum levels of gentamicin in endocardi-
tis patients. Based on these results, one of the PPK models could be recommended for use.
Materials and methods
MW\Pharm version 3.82 (Mediware, Groningen, the Netherlands) was used to perform PPK
analyses, to develop the endocarditis model, and validate all three models in endocarditis
patients.
Patient data
A retrospective observational cohort study was performed with pharmacy data from patients
treated at two Dutch university/tertiary hospitals: The Hague Hospitals and the University
Medical Center Groningen (UMCG). Inclusion comprised patients18 years of age, with
data available about weight, height, gender, serum creatinine, gentamicin dosing and total gen-
tamicin serum levels. Exclusion comprised patients with incomplete data, and patients on dial-
ysis as this influences the gentamicin clearance. Medical records of all patients present in the
hospital databases for gentamicin administration were studied to select eligible patients. If sep-
arate episodes of endocarditis were detected for a patient, these episodes were included as sepa-
rate patients in our analyses. Data from The Hague Hospitals was used to develop a new PPK
model (the modeling cohort; n = 65). Patients in the modeling cohort received intravenous
gentamicin between 2011 and 2013. Data from the UMCG was used to validate the models
(validation cohort; n = 14). Patients in the validation cohort received intravenous gentamicin
between 2012 and 2014.
Phase 1: Pharmacokinetic analysis and endocarditis model
development
To develop the endocarditis model, the Kinpop module in MW\Pharm V3.82 was used to per-
form Iterative Two-Stage Bayesian (ITSB) analysis with serum levels from the modeling
cohort. Inter-individual variability of the PK parameters was assumed to be distributed log-
normally.
ITSB [25] needed initial estimates for each population parameter (mean and standard devi-
ation (SD)) to start the iterative process. Thereafter, each patient’s PK parameters were deter-
mined based on its own measurements and the estimated population parameters as Bayesian
priors. Then, the population mean and SD of each parameter were calculated from the
patient’s parameters. These stages were repeated in the next cycle using previous population
parameters as Bayesian priors, until the population parameters were fixed. ITSB has been
shown to provide reasonable estimates for population parameters [19].
One-compartment models with first-order elimination were created, with estimates for
metabolic/non-renal clearance (CLm), renal gentamicin clearance as a fraction of creatinine
clearance (fr), and volume of distribution (Vd). For calculation of the clearance (CL) we chose
the formula with total bodyweight (BW) and creatinine clearance of gentamicin according to
Cockroft-Gault [26] (CLcr): CL = CLm(BW/70) + frCLcr. This standard formula was chosen
as it is clinically easy to use, serving applicability and simplicity for users. Furthermore, this
approach enables a direct comparison as the ICU and standard models use this formula, too
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[24]. For volume of distribution, a unit of liter per kilogram of lean body mass according to the
equation of Chennavasin [27] corrected for fat distribution [28] was used.
Different modified PPK models were designed, starting with population parameters pro-
vided by either the ICU or standard model. All newly designed PPK models were fitted to the
data of the modeling cohort by testing different settings in MW\Pharm for the included PK
parameters. Three settings exist in MW\Pharm for inclusion of pharmacokinetic parameters
of a model: estimated with Bayesian prior (“Bayesian”), estimated with a predefined fixed pop-
ulation value (fixed population Bayesian, “FPB”), or set to a fixed value (“Fixed”).
The goodness-of-fit of the newly designed PPK models were evaluated using the Akaike
Information criterion (AIC), and the weighted sum of squares of the residuals of concentration
measurements and parameters (SWSS) divided by the degrees of freedom (df; the total num-
ber of measurements minus the number of estimated population and individual parameters)
(SWSS/df). Both AIC and SWSS/df were aimed to be as close to zero as possible. The newly
designed PPK model most reliably predicting gentamicin serum level in the modeling cohort
(based on the AIC and SWSS/df closest to zero) was selected: the endocarditis model. To eval-
uate the significance of the covariates, a stepwise covariate analysis was performed, starting
with a model without covariates. Nonparametric 95% confidence intervals of the population
parameters for this model were obtained by bootstrap analysis with 1000 repetitions, which
could be considered as a resampling technique for internal validation.
Phase 2: Model validation and comparison
External validation of the standard, ICU, and endocarditis models was performed using
patient data from the validation cohort, as this provides the strongest evidence for model vali-
dation. The Kinpop module in MW\Pharm was used with one cycle set as a maximum. In this
setting, MW\Pharm determines the predictive power of a PPK model (a model’s ability to pre-
dict serum levels of an individual patient), as opposed to the iterative procedure for the fitting
of a new PPK model to population data. CLm was fixed (“Fixed”) on a literature value [19,24],
and for parameters fr and Vd Bayesian fitting was used (“FPB”).
The MDAPE (Median Absolute Prediction Error) and MDPE (Median Prediction Error)
were used as criteria to assess which of the three models (the standard, ICU, or endocarditis
model) predicted the serum levels of gentamicin most accurately in patients with endocarditis.
In order to calculate the MDPE and MDAPE, measured gentamicin serum levels and predicted
levels by the models were extracted from MW\Pharm. MDPE is a measure of bias, which is the
median of the prediction errors for each serum sample. The predictive errors are calculated
using: PE = (Cpredicted—Cobserved) / Cobserved. MDAPE is a measure of precision, which is the
median of the absolute values of the prediction errors. Nonparametric 95% confidence inter-
vals of MDPE and MDAPE were obtained by bootstrap analysis with 10,000 repetitions.
Gentamicin assay
Gentamicin levels of serum samples drawn in the validation cohort before 2013, were deter-
mined using fluorescence polarization immunoassays on an AxSym automated analyzer
(Abbott Laboratories, Chicago, IL, USA). Levels of serum samples drawn in the modeling
cohort, and in the validation cohort after 2013, were determined using an enzyme multiplied
immunoassay technique (EMIT) with an Architect Analyzer (Abbott Laboratories).
The lower limit of quantification for the EMIT technique was 0.2 mg/L. Since most samples
were measured by the EMIT technique, the assay error for this technique was used for model-
ing. The assay error, describing the measuring error over the range of existent serum levels, is
described by the following equation: SD = 0.0766 + 0.0006 C + 0.0064 C2.
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Ethical permission
A waiver was obtained for this research from the medical ethical committee in the UMCG for
the act about Medical Research Involving Human Subjects (in Dutch: WMO) [date: July 29,
2014; file reference: M14.159588]. In addition, the board of directors of the Pharmacy The
Hague Hospitals has approved the use of the anonymised data.
Statistics
Demographic data of the modeling population and validation population were statistically
compared in SPSS (IBM Predictive Analytics-software) using two sided Student’s t-tests.
Equality of variances were tested with F-tests.
Results
Patient data
After patient selection, the modeling cohort contained 65 patients with 221 serum samples,
and the validation cohort contained 14 patients with 30 serum samples. Only one patient from
the validation cohort had two separate episodes of endocarditis. Table 1 shows the demo-
graphic data and clinical characteristics of the modeling and validation cohorts. There were no
significant differences between the cohorts, with a limit for significance of p<0.05.
Fig 1 shows a simulation of the serum levels in the ICU model of a standard patient from
the modeling cohort after the standard administration of 3 mg/kg gentamicin for endocarditis
(blue line), with the 95% prediction interval (shaded area). It shows that the large variability in
PK parameters results in a large variability in gentamicin serum levels between patients. Fig 2
shows the decrease in prediction uncertainty (shaded area) after TDM.
Phase 1: Pharmacokinetic analysis and model development
Table 2 summarizes the ‘a priori’ population parameters used as starting point, the fitting set-
tings, and the resulting AIC and SWSS/df values for all newly developed PPK models. The
best fitting PPK model for the modeling cohort based on AIC and SWSS/df was parameterized
with CLm fixed and Bayesian estimations for fr and Vd. The results of the stepwise covariate
analysis (S1 Table), show that the model selected based on the description in the methods sec-
tion results in the lowest AIC and thus should be regarded as the best model.
Diagnostic plots of measured concentrations versus predicted concentrations (Fig 3) and
weighted residuals versus measured concentrations (Fig 4) showed a trend of the measured
concentrations being higher than the predicted concentrations by the endocarditis model for
Table 1. Demographic data and clinical characteristics of the modeling and validation cohorts.
Characteristic Modeling cohort (n = 65) Validation cohort (n = 14)
Mean Range Mean Range P-value
Age (years) 69.3 32–92 63.4 30–88 0.12
Weight (kg) 76.2 46–121 80.3 65–90 0.12
Height (cm) 173.9 149–193 177.7 169–195 0.18
Gender 21F/44M - 3F/11M -
CLcr (ml/min) 64.3 8.7–157.5 75.5 28.4–181.5 0.32
CLcr (ml/min/1.73m2) 58.4 7.8–153.2 65.6 23.9–141.1 0.47
CLcr = creatinine clearance, m2 = square meter body surface area. (S1 Data).
https://doi.org/10.1371/journal.pone.0177324.t001
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concentrations above about 10–12 mg/L. There was no deflection of interest below this rele-
vant range for infective endocarditis. This phenomenon was observed in the diagnostic plots
of each of the models described in Table 2. Table 3 shows the estimated mean population
parameters (± SD) for the selected endocarditis model, and for the clinically used ICU and
standard models.
Phase 2: Model validation and comparison
The three PPK models (standard, ICU, endocarditis) were validated in the validation cohort.
Table 4 shows the calculated MDPE and MDAPE. The ICU model yielded the best fit to the
data of the validation cohort based on MDAPE. This held true for the standard model based
on MDPE. As MDAPE is a reliable criterion, and to retain simplicity in clinical practice, the
ICU model was selected as best model to accurately predict gentamicin serum level in endocar-
ditis patients routinely. There was no trend of the measured concentrations visible in the vali-
dation cohort for either of the three models, as shown in Fig 5 for the ICU model.
Discussion
The large inter individual variability seen in serum levels with a fixed starting dose of 3 mg/kg
gentamicin (as depicted by the shaded area in Fig 1), and the spectacularly smaller variability
seen with dosing based on two measured serum concentrations (as depicted by the shaded
area in Fig 2), clarifies the need for TDM. TDM should start at day 1 of gentamicin administra-
tion, to increase the likelihood of therapeutic and non-toxic gentamicin levels as soon as
Fig 1. Simulation in the ICU model of a standard patient from the modeling cohort and the standard
administration of 3 mg/kg gentamicin. Standard patient (see Table 1): male of 70 years old, 76.2 kg, and
174 cm, with a serum creatinin concentration of 86 μmol/L and a CLcr of 58 ml/min/1.73 m2. Fig 1 shows that
the large variability in PK parameters results in a large variability in gentamicin serum levels between patients
(see shaded area for 95% confidence interval). Therefore, TDM is needed from the first day of gentamicin
administration.
https://doi.org/10.1371/journal.pone.0177324.g001
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possible. Therefore, a new PPK model for the prediction of gentamicin serum levels in endo-
carditis patients was created in this study using a modeling cohort. The endocarditis model
was selected based on the observed goodness-of-fit (AIC and SWSS/df as close to zero as pos-
sible, see Table 2), presenting a CLm fixed at 0.277 l/h/70kgBW, and Bayesian fitting for fr at
0.698 (±0.358) and Vd at 0.312 L/kg LBMc (±0.076). During the external validation phase of
this study, in which the three models were compared for their ability to predict serum genta-
micin concentrations in the validation cohort, it was the ICU model showing the best fit
Fig 2. Bayesian simulation in the ICU model of a standard patient from the modeling cohort and the
standard administration of 3 mg/kg gentamicin. Standard patient (see Table 1): male of 70 years old, 76.2
kg, and 174 cm, with a serum creatinin concentration of 86 μmol/L and a CLcr of 58 ml/min/1.73 m2.
Prediction and spectacularly smaller 95% confidence interval (shaded area) as compared with Fig 1, for an
individual based on two measurements of the gentamicin concentration in serum (purple cross): sample 1 on
t = 1 h (30 minutes after the 30 minute infusion of gentamicin) with a concentration of 8 mg/L, and sample 2 on
t = 4.5 h (4 hours after the 30 minutes infusion of gentamicin, with a concentration of 5 mg/L.
https://doi.org/10.1371/journal.pone.0177324.g002
Table 2. Fitting settings used for model development with ITSB and the resulting parameters. In bold the selected endocarditis model, based on the
AIC and ΣWSS/df as close to zero as possible. AIC = Akaike Information criterion, CLm = metabolic or non-renal clearance, fr = renal gentamicin clearance as
a fraction of creatinine clearance, FPB = fixed population Bayesian, ICU = Intensive Care Unit, Vd = volume of distribution, ΣWSS/df = sum of the weighted
sum of squares of the concentrations and parameters divided by the degrees of freedom. (S2 Data).
Population parameters Settings AIC ΣWSS/df
CLm fr Vd
ICU model Bayesian Bayesian Bayesian 1394 5.05
FPB Bayesian Bayesian 1309 5.09
Fixed Bayesian Bayesian 1195 5.25
Standard model Bayesian Bayesian Bayesian 1394 5.05
FPB Bayesian Bayesian 1306 5.08
Fixed Bayesian Bayesian 1204 5.30
https://doi.org/10.1371/journal.pone.0177324.t002
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(MDPE and MDAPE as close to zero as possible [29], see Table 4). Some points of this study
are worth a discussion in more detail.
The parameterized Vd in the endocarditis model (0.312 ±0.076 L/kg LBMc) lies in between
those of the standard (0.273 ±0.082 L/kg LBMc) and ICU (0.335 ±0.104 L/kg LBMc) models.
Fig 3. Diagnostic plot of measured concentrations versus predicted concentrations by the
endocarditis model of gentamicin in the modeling cohort.
https://doi.org/10.1371/journal.pone.0177324.g003
Fig 4. Diagnostic plot of weighted residuals (measured concentration minus predicted
concentrations by the endocarditis model of gentamicin, divided by the standard deviation of the
assay error) versus measured concentrations of gentamicin in the modeling cohort.
https://doi.org/10.1371/journal.pone.0177324.g004
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Our present day cohort represents adult patients with endocarditis diagnosed according to the
modified Duke criteria [30], with a relatively high percentage of intracardiac prosthetic mate-
rial in situ, and treated with gentamicin dosed once daily. Similar findings were previously
described by Rosell-Rovira et al. [23], who found a Vd of 0.29 L/kg in their historical cohort of
Table 3. Population parameters for gentamicin for ICU and standard models and the best newly developed endocarditis model (with nonparamet-
ric 95% confidence interval [CI] obtained by bootstrapping).
PK parameter CLm (L/h/70kgBW) fr Vd (L/kgLBMc)
mean SD mean SD mean SD
ICU model 0.277 0.138 0.899 0.417 0.335 0.104
Standard model 0.225 0.113 0.727 0.471 0.273 0.082
Endocarditis model 0.277 0 0.698 0.358 0.312 0.076
95% CI [0.610; 0.794] [0.273; 0.435] [0.292; 0.331] [0.060; 0.091]
BW = body weight, CLm = metabolic or non-renal clearance, fr = renal gentamicin clearance as a fraction of creatinine clearance, ICU = Intensive Care Unit,
LBMc = lean body mass according to the equation of Chennavasin [27] corrected for fat distribution [28], SD = standard deviation, Vd = volume of
distribution. (S2 Data).
https://doi.org/10.1371/journal.pone.0177324.t003
Table 4. Validation parameters (with nonparametric 95% confidence interval [CI] obtained by bootstrapping) for comparison between models
should be as close to zero as possible.

















MDPE = Median Absolute Prediction Error, MDAPE = Absolute Median Prediction Error, ICU = Intensive Care Unit. (S3 Data).
https://doi.org/10.1371/journal.pone.0177324.t004
Fig 5. Diagnostic plot of measured concentrations versus predicted concentrations by the ICU model
in the validation cohort.
https://doi.org/10.1371/journal.pone.0177324.g005
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adult patients with endocarditis according to the at the time conventional diagnostic criteria
[31] and presumably treated with fractionated dosing of gentamicin. Even though our finding
cannot be directly compared to the Vd reported by Rosell-Rovira et al. as measuring units dif-
fer, our data consolidate the evidence for a Vd of endocarditis patients being more similar to
the Vd of ICU patients than to the Vd of standard ward patients, as they were previously
reported for populations from the same geographical area, treated according to similar regi-
mens and protocols, and investigated with comparable methodology [24]. This is important as
the standard model is generally used for gentamicin dosing in endocarditis patients, and the
presumed lower Vd in this model causes measured serum peak levels to be lower than pre-
dicted and required for therapeutic efficacy [19]. Potential complications of endocarditis
underlying this increased Vd, include: 1) cardiac complications such as congestive heart failure
[32], acute pericarditis and myocarditis [23]; and 2) infectious complications such as fever and
sepsis [12].
The ITSB methodology used in our analysis is potentially less precise and newer methods,
e.g. NONMEM, may have advantages as a methodology in purely scientific analyses but not in
clinical practice. Offsetting, ITSB has been shown to compare well with several newer methods
including NONMEM [25,33], and current clinically used TDM software is not able to work
with NONMEM output directly. Therefore, to increase external validity and usability in clini-
cal practice, we chose to use the ITSB method implemented in MW\Pharm as this output can
be used directly in daily practice.
For a good estimation of CLm, patients with poor renal function have to be included in the
modeling population. Inclusion of patients on dialysis would have provided such information.
However, we chose to exclude these patients, as the extraction ratio of a dialysis membrane
would add another significant uncertainty factor to the model. This extraction ratio needs esti-
mation, depending on factors such as volume extraction, flow rate, the type and age of the dial-
ysis membrane. Consequently, our modeling population contained only <10% of patients
with a renal function <15ml/min and we were unable to estimate CLm reliably. Therefore, we
chose to fix the parameter for CLm at a value previously determined in a comparable popula-
tion [19,24], under the assumption that endocarditis would not affect metabolic clearance of
gentamicin.
The performance of the endocarditis model in the modeling cohort differed from that in
the validation cohort. This resulted from a large standard deviation (SD) for all estimated PK
parameters in the endocarditis model and a relatively small validation cohort. Large SDs of PK
parameters resulted from large inter individual variability in serum levels of gentamicin and
omnipresent methodological errors which should be minimized by standardizing protocols
(blood sampling, drug dose preparation, recording of the time point of gentamicin administra-
tion and blood sampling, gentamicin assay, data handling). Furthermore, as information
about height and weight of patients is essential for accurate model development and validation,
a considerable number of patients missing this information needed exclusion from our valida-
tion cohort.
Future research could cover the validation of the peak level range of 9–12 mg/l for once
daily administration of gentamicin in endocarditis. This therapeutic target range is narrow
[23], and has been extensively validated for fractionated dosing but not for once daily dosing.
Of note, drug assays have been calibrated to yield the most reliable results within the level
range normally found by fractionated dosing [16]. Future research could also focus on the
(patho)physiology of the increased Vd in endocarditis patients, as we were unable to deduce
this in our study.
Neither the standard, ICU, nor the endocarditis PPK model had clearly superior predictive
power in our study. We conclude that the standard and ICU models are robust enough to
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resist variability of relevant characteristics in endocarditis patients, and at the same time pro-
vide acceptable predictive power for estimation of gentamicin serum levels. We advise to gen-
erally use the ICU model for gentamicin dosing in endocarditis patients, based on its best fit to
the data of our validation cohort, the demand to treat endocarditis aggressively as soon as pos-
sible, and our ambition to maintain simplicity and thus safety in clinical practice. Taking into
account the larger Vd found in endocarditis patients in the modeling phase of our study, and
the fact that Vd prominently determines serum peak levels of gentamicin which in turn corre-
lates with its bactericidal activity, endocarditis patients need higher gentamicin doses than
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